Pharmaceutical

Coeptis licenses Deverra Therapeutics’ clinical stage assets

Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.

Aug 18, 2023 - 20:00
Coeptis licenses Deverra Therapeutics’ clinical stage assets
Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.
Read the original article

Tags:

Previous Article

Signal: Abortion pill restriction may drive more patients to off-label drug

Next Article

Bruker to buy cell biology company PhenomeX for $108m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Drug shortages challenge type 2 diabetes patients in the UK

Drug shortages challenge type 2 diabetes patients in th...

Jan 27, 2024

Alumis raises $250m in IPO as biotech stock stirs

Alumis raises $250m in IPO as biotech stock stirs

Jun 30, 2024

Kidney doctors push to protect patients by including dialysis machines in emergency stockpile

Kidney doctors push to protect patients by including di...

Aug 7, 2023